Last updated on March 2019

Prevention of Episodic Migraine: Long-Term, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Oral Atogepant

Brief description of study

This purpose of this study is to evaluate the safety and tolerability of 52 weeks of treatment with an investigational study medication, atogepant for the prevention of migraine headaches. 

Study participation may last up to 60 weeks and include up to 16 visits to the research center.

After an initial screening visit, patients will participate in a 28 day observational period.  Participants who continue to meet eligibility criteria at the end of the observational period will be randomly assigned to either the investigational study medication or a “standard of care” medication (a medication that is recognized as safe and effective for the prevention of migraine) for 52 weeks. 

Participants will be asked to come in for a follow-up visit 4 weeks after the last dose.


Clinical Study Identifier: TX217990

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.